Drug – bio-affecting and body treating compositions – Lymphokine
Reexamination Certificate
2006-08-08
2006-08-08
O'Hara, Eileen B. (Department: 1646)
Drug, bio-affecting and body treating compositions
Lymphokine
C424S192100, C530S351000, C514S012200
Reexamination Certificate
active
07087225
ABSTRACT:
The present invention concerns methods for diagnosis and treatment of metabolic bone diseases and disorders using a novel member of the tumor necrosis factor (TNF) family of cytokines. In particular the invention provides methods of using the Endokine alpha protein and/or homomultimeric and/or heteromultimeric polypeptide complexes containing Endokine alpha, in the diagnosis, prognosis and treatment of metabolic bone diseases and disorders. Also provided by the invention are methods of using the Endokine alpha protein and/or homomultimeric and/or heteromultimeric polypeptide complexes containing Endokine alpha, in the diagnosis, prognosis and treatment of diseases and/or disorders associated with aberrant osteoclast development and/or activity. The present invention also provides isolated polynucleotides encoding polypeptides of the invention, antibodies thereto, and agonists and antagonists thereof, for use in the diagnosis, prognosis and treatment of metabolic bone diseases and disorders.
REFERENCES:
patent: 5288852 (1994-02-01), Yamada et al.
patent: 5998171 (1999-12-01), Yu et al.
patent: 6406867 (2002-06-01), Yu et al.
patent: 6521742 (2002-06-01), Yu et al.
patent: 2002/0099198 (2002-07-01), Yu et al.
patent: 2002/0146389 (2002-10-01), Ashkenazi et al.
patent: 2002/0168729 (2002-11-01), Yu et al.
patent: 0 212 489 (1987-03-01), None
patent: 0 218 868 (1987-04-01), None
patent: 0 288 088 (1988-11-01), None
patent: WO 96/14328 (1996-05-01), None
patent: WO 00/50620 (2000-08-01), None
See Locksley et al., Cell, vol. 104, pp. 487-501, Feb. 23, 2001.
U.S. Appl. No. 09/912,293, Rosen et al., Not Published.
Aggarwal, B.B., and Natarajan, K., “Tumor necrosis factors: Developments during the last decade,”Eur. Cytokine Netw. 7:93-124, John Libbey Eurotext (Apr.-Jun. 1996).
Beutler, B., et al., “Passive Immunization Against Cachectin/Tumor Necrosis Factor Protects Mice from Lethal Effect of Endotoxin,”Science 229:869-871, American Association for the Advancement of Science (1985).
Bowie, J.U., et al., “Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions,”Science 247:1306-1310, American Association for the Advancement of Science (1990).
Bringman, T.S., and Aggarwal, B.B., “Monoclonal Antibodies to Human Tumor Necrosis Factors Alpha and Beta: Application for Affinity Purification, Immunoassays, and as Structural Probes,”Hybridoma 6:489-507, Mary Ann Liebert, Inc. (1987).
Doerks, T., et al., “Protein annotation:detective work for function prediction,”Trends Genet. 14:248-250, Elsevier Science B. V. (Jun. 1998).
Elliott, M.J., and Maini, R.N., “Anti-cytokine therapy in rheumatoid arthritis,”Baillière's Clin. Rheum. 9:633-652, Baillière Tindall (Nov. 1995).
Feldmann, M., et al., “TNFα Is an Effective Therapeutic Target for Rheumatoid Arthritis,”Ann. N.Y. Acad. Sci. 766:272-278, New York Academy of Sciences (Nov. 1995).
Fendly, B.M., et al., “Murine Monoclonal Antibodies Defining Neutralizing Epitopes on Tumor Necrosis Factor,”Hybridoma 6:359-370, Mary Ann Liebert, Inc. (1987).
Gruss, H-J., and Dower, S.K., “Tumor Necrosis Factor Ligand Superfamily: Involvement in the Pathology of Malignant Lymphomas,”Blood 85:3378-3404, W.B. Saunders Co. (Jun. 1995).
Gurney, A.L., et al., “Identification of a new member of the tumor necrosis factor family and its receptor, a human ortholog of mouse GITR,”Curr. Biol. 9:251-218, Elsevier Science Ltd. (1999).
Hillier, L., et al. Database EST-STN on MASPAR search, WashU-Merck EST Project, (St. Louis, Mo, USA), No. R38487, “yf60c04.s1 Homo sapiens cDNA clone 26749 3′,” (May 1995).
Hillier, L., et al. Database EST-STN on MASPAR search, WashU-Merck EST Project, (St. Louis, MO., USA) No. R41403, “yf94c12.s1 Homo sapiens cDNA clone 30225 3′,” (May 1995).
Hinshaw, L.B., et al., “Survival of Primates in LD100Septic Shock Following Therapy With Antibody to Tumor Necrosis Factor (TNFα),”Circ. Shock 30:279-292, Wiley-Liss, Inc. (1990).
Hirai, M., et al., “Production and characterization of monoclonal antibodies to human tumor necrosis factor,”J. Immunol. Methods 96:57-62, Elsevier Science B.V. (1987).
Kriegeler, M., et al., “A Novel Form of TNF/Cachectin Is a Cell Surface Cytotoxic Transmembrane Protein: Ramifications for the Complex Physiology of TNF,”Cell 53:45-53, Cell Press (1988).
Kwon, B., et al., “Identification of a Novel Activation-inducible Protein of the Tumor Necrosis Factor Receptor Superfamily and Its Ligand,”J. Biol. Chem. 274:6056-6061, American Society for Biochemistry and Molecular Biology, Inc. (1999).
Liang, C-M., et al., “Production and Characterization of Monoclonal Antibodies Against Recombinant Human Tumor Necrosis Factor/Cachectin,”Biochem. Biophys. Res. Comm. 137:847-854, Academic Press, Inc. (1986).
Mathison, J.C., et al., “Participation of Tumor Necrosis Factor in the Mediation of Gram Negative Bacterial Lipopolysaccharide-induced Injury in Rabbits,”J. Clin. Invest. 81:1925-1937, Rockefeller University Press (1988).
Meager, A., et al., “Preparation and Charcterization of Monoclonal Antibodies Directed Against Antigenic Determinants of Recombinant Human Tumour Necrosis Factor (rTNF),”Hybridoma 6:305-311, Mary Ann Liebert, Inc. (1987).
Mikayama, T., et al., “Molecular cloning and functional expression of a cDNA encoding glycosylation-inhibiting factor,”Proc. Natl. Acad. Sci. USA 90:10056-10060, National Academy of Sciences of the USA (1993).
Miki, Y., et al., Database EST-STN on MASPAR search, GenBank No. S78214, “Disruption of the APC gene by retrotransposal insertion of L1 sequence in a colon cancer,”0Cancer Research 52:643-5 (1992).
Möller , A., et al., “Monoclonal Antibodies to Human Tumor Necrosis Factor α: In Vitro and In Vivo Application,”Cytokine 2:162-169, W.B. Saunders Co. (1990).
Opal, S.M., et al., “Efficacy of a Monoclonal Antibody Directed against Tumor Necrosis Factor in Protecting Neutropenic Rats from Lethal Infection withPseudomonas aeruginosa,” J. Infect. Dis. 161:1148-1152, University of Chicago Press (1990).
Shimamoto, Y., et al., “Monoclonal antibodies against human recombinant tumor necrosis factor: prevention of endotoxic shock,”Immunol. Letters 17:311-318, Elsevier Science B.V. (1988).
Silva, A.T., et al., “Prophylactic and Therapeutic Effects of a Monoclonical Antibody to Tumor Necrosis Factor-α in Experimental Gram-Negative Shock,”J. Infect. Dis. 162:421-427, University of Chicago Press (1990).
Smith, R.A., and Baglioni, C., “The Active Form of Tumor Necrosis Factor Is a Trimer,”J. Biol. Chem. 262:6951-6954, American Society of Biological Chemists, Inc. (1987).
Tracey, K.J. et al., “Anti-cachetin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia,”Nature 330:662-664, Macmillan Journals Ltd. (1987).
Tracey, K.J., and Cerami, A., “Tumor necrosis factor: An updated review of its biology,”Crit. Care Med. 21:S415-S422, Williams & Wilkins (1993).
Van Der Poll, T., and Lowry, S.F., “Tumor Necrosis Factor in Sepsis: Mediator of Multiple Organ Failure or Essential Part of Host Defense?”Shock 3:1-12, BioMedical Press (Jan. 1995).
Voet, D., and Voet, J.G., “Sickle-Cell Anemia: The Influence of Nature Selection,” and “Abnormal Hemoglobins,” inBiochemistry, Voet, D., and Voet, J.G., eds., John Wiley & Sons, Inc., New York, NY, pp. 126-128 and 228-234 (1990).
Wherry, J.C., et al., “Tumor necrosis factor and the therapeutic potential of anti-tumor necrosis factor antibodies,”Crit. Care Med. 21:S436-S440, Williams & Wilkins (1993).
Wiley, S.R., et al, “Identification and Characterization of a New Member of the TNF Family that Induces Apoptosis,”Immunity 3:6
Nardelli Bernadetta
Ni Jian
Rosen Craig A.
Yu Guo-Liang
Human Genome Sciences Inc.
Human Genome Sciences Inc.
O'Hara Eileen B.
LandOfFree
Methods and compositions for treating metabolic bone... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for treating metabolic bone..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for treating metabolic bone... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3645344